Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2001-11-01
2004-04-06
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S069400, C435S071200, C435S252800, C435S243000
Reexamination Certificate
active
06716602
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to improvements in product yield from fermentation to produce recombinant proteins, particularly in prokaryotic and simple eukaryotic systems. More particularly, this invention greatly increases the yield of properly assembled proteins in large scale fermentations.
BACKGROUND OF THE INVENTION
The production of large quantities of relatively pure, biologically active polypeptides and proteins is important economically for the manufacture of human and animal pharmaceutical formulations, enzymes, and other speciality chemicals. Recombinant DNA techniques have become the method of choice to produce large quantities of exogenous proteins using bacteria and other host cells. The expression of proteins by recombinant DNA techniques for the production of cells or cell parts that function as biocatalysts is also an important application.
Producing recombinant protein involves transfecting host cells with DNA encoding the protein and growing the cells under conditions favoring expression of the recombinant protein. The prokaryote
E. coli
is favored as host because it can be made to produce recombinant proteins in high yields. Numerous U.S. patents on general bacterial expression of DNA encoding proteins exist, including U.S. Pat. No. 4,565,785 on a recombinant DNA molecule comprising a bacterial gene for an extracellular or periplasmic carrier protein and a non-bacterial gene; U.S. Pat. No. 4,673,641 on co-production of a foreign polypeptide with an aggregate-forming polypeptide; U.S. Pat. No. 4,738,921 on an expression vector with a trp promoter/operator and trp LE fusion with a polypeptide such as IGF-I; U.S. Pat. No. 4,795,706 on expression control sequences to include with a foreign protein; U.S. Pat. No. 4,710,473 on specific circular DNA plasmids such as those encoding IGF-I; U.S. Pat. No. 5,342,763 on improving expression in bacteria by manipulating oxygen delivery; and U.S. Pat. No. 5,639,635 on secretion of the expressed protein into the bacterial periplasm.
Recombinant proteins become less expensive if the fermentation yield improves. Yield depends upon the rate at which the recombinant protein is properly folded and assembled protein is formed and upon the length of time over which the protein is produced.
The recombinant protein expression rate is typically affected by the growth and metabolic rates of the cells. At higher growth rates, the rate at which a protein can be expressed when induced typically increases (Curless et al., Biotechnol. Prog. 1990, 6:149). However, upon induction, high protein expression rates may not always lead to high rates of formation of active, properly formed products. In other words, while the quantity of protein translated may be maximized, other factors may compromise the quality of the product, such as degradation of the protein by proteases or other detrimental post-translational modifications (Ryan et al., Biotechnol. Prog. 1996, 12:596; Yoon et al., Biotechnol. Prog. 1994, 43:995). Efficient fermentation requires balancing growth rate against yield of usable protein; compromises between these factors result in a decrease of the overall yield below its theoretical potential. Consequently, some intermediate growth rates may be more favorable for the production of high quantities of high quality product.
An added complication is that induction of recombinant protein expression essentially highjacks the cellular protein assembly process to make large quantities of a product with no benefit, and often with significant detriment, to the cell. In fact, for cases in which induction is triggered by phosphate depletion using the alkaline phosphatase promoter, growth rate is dramatically curtailed by the phosphate starvation itself. This effect does not affect the metabolic rate, however.
Thus, there is a need in the art to increase the yield of usable recombinant protein production. The present invention advantageously and unexpectedly addresses this need by permitting high levels of protein synthesis, assembly and folding. Because different factors may play critical roles in maximizing usable protein yield prior to induction during the growth phase of the culture, and post-induction, the independent control of these two factors can lead to improved yields of usable products, such as for the case of soluble, properly folded and assembled antibody fragments.
SUMMARY OF THE INVENTION
The invention provides a method for increasing product yield of a polypeptide of interest produced by recombinant host cells, where expression of the polypeptide by the recombinant host cells is regulated by an inducible system. More specifically, the method involves culturing the recombinant host cells under conditions of high metabolic and growth rate, then reducing the metabolic rate of the recombinant host cells at the time of induction of polypeptide expression.
In a specific embodiment the invention provides a method of increasing product yield of an antibody, growth factor, or protease produced by a recombinant
E. coli
host cell regulated by an inducible system.
In a further specific embodiment, the invention provides a method of increasing the yield of actively folded proteins having different structures, for example Fab′
2
versus Fab Fv antibody fragments, by selecting the time to initiate reduction in metabolic rate (the rate shift), the rate of adjustment (shift) of the metabolic rate, and the final metabolic rate. Adjusting these parameters of the invention enhances the yield of correctly folded proteins having different secondary and tertiary structures, interaction and refolding characteristics, size and contact area, and other factors that can affect protein assembly and function.
REFERENCES:
patent: 4565785 (1986-01-01), Gilbert et al.
patent: 4673641 (1987-06-01), George et al.
patent: 4710473 (1987-12-01), Morris
patent: 4738921 (1988-04-01), Belagaje et al.
patent: 4795706 (1989-01-01), Hsiung et al.
patent: 5342763 (1994-08-01), Schwartz
patent: 5612198 (1997-03-01), Brierley et al.
patent: 5639635 (1997-06-01), Joly et al.
patent: 5789199 (1998-08-01), Joly et al.
patent: 6410270 (2002-06-01), Strittmatter et al.
patent: 19943919 (2001-03-01), None
Flamez et al., Production inEscherichia coliof a functional murine and murine::human chimeric F (ab′)2 fragment and mature antibody directed against human placental alkaline phosphatase, 1995, Journal of Biotechnology, vol. 42, pp. 133-143.*
Knorre et al., High cell density fermentation of recombinantEscherichia coliwith computer-controlled optimal growth rate, 1991, Ann. NY. Acad. Sci., vol. 646, pp. 300-306.*
Skerra et al., Use of tetracycline promoter for the tightly regulated production of a murine antibody fragment inEscherichia coli, 1994, Gene, vol. 151, pp. 131-135.*
Gram et al., A novel approach for high level production of a recombinant human parathyroid hormone fragment inEscherichia coli, 1994, Bio/Technology, vol. 12, pp. 1017-1023.*
Cheng et al., “A Novel Feeding Strategy for Enhanced Plasmid Stability and Protein Production in Recombinant Yeast Fedbatch Fermentation.”Biotechnol. Bioeng.56:23-31 (1997).
Cruz et al., “Metabolic Shifts by Nutrient Manipulation in Continuous Cultures of BHK Cells.”Biotechnol. Bioeng.66:104-113 (1999).
Cruz et al., “Metabolically Optimised BHK Cell Fed-Batch Cultures.”J. Biotechnology.80:109-118 (2000).
Curless et al., Biotechnol. Prog. 1990, 6:149.
Ryan et al., Biotechnol. Prog. 1996, 12:596.
Yoon et al., Biotechnol. Prog. 1994, 43:995.
Villa-Komaroff, et al., Proc. Natl. Acad. Sci. USA 1978, 75:3727-373.
DeBoer et al., Proc. Natl. Acad. Sci. USA 1983, 80:21-25.
Sheibani, Prep. Biochem. Biotechnol. 1999, 29:77.
Gossen et al., Curr. Opin. Biotechnol. 1994, 5:516.
De Vos et al., Curr. Opin. Biotechnol. 1997, 8:547.
Chevalet et al., Biotechnol. Bioeng. 2000, 69:351.
Schroeckh et al., J. Biotechnol. 1999, 75:241.
Staijen et al., J. Bacteriol. 1999, 181:1610.
Newman and Fuqua, Gene 1999, 277:197.
Liu et al., Biotechniques 1998, 24:624.
Gallia and Khalili, Ongogene 1998, 16:1879.
Haldimann et al.,
Andersen Dana
Joly John
Snedecor Bradley R.
Genentech Inc.
Guzo David
Hasak Janet E.
Sullivan Daniel M.
LandOfFree
Metabolic rate shifts in fermentations expressing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metabolic rate shifts in fermentations expressing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metabolic rate shifts in fermentations expressing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3239084